Pfizer’s love affair with carcinogens continues with Aprela®

UPDATE: Aprela approved by the FDA during last federal government shutdown under the name Duavee. Written by JANE ALLIN Pfizer’s recent announcement to seek U.S. regulatory approval for their combined menopausal-osteoporosis drug Aprela® is nothing short of an appalling money grab and a ruse to defer negative focus from their controversial hormone-replacement therapies – Prempro®…

Pfizer to Withdraw Fablyn NDAs

Written by JANE ALLIN Research Analyst Pfizer, the world’s largest drug maker, has announced the withdrawal of its new drug application (NDA) for Fablyn® a selective estrogen receptor modulator (“SERM”) for the treatment of both osteoporosis and selected consequences of menopause. As with other SERMs, Fablyn® has been shown to have significant side-effects which contraindicate…